India reaffirmed its role as the pharmacy of the world during COVID: JP Nadda addresses 19th International Conference of Drug Regulatory Authorities

New Delhi: Union Minister of Chemicals and Fertilisers JP Nadda, during his address at the 19th International Conference of Drug Regulatory Authorities (ICDRA), hailed India's crucial role during the Covid-19 pandemic and how the country is emerging as a global leader in health resilience and innovation, thereby reaffirming its position as the 'pharmacy of the world.'
The Union Minister welcomed the participants of the event, highlighting its importance as a platform for experts and leaders from over 120 countries.
"It is an honour and privilege to welcome you all to the 19th ICDRA. This prestigious platform reflects our shared commitment to enhancing global healthcare standards and safeguarding public health," Nadda said.
Speaking about India's role during the Covid-19 pandemic, he said, "During the unprecedented Covid-19 pandemic, India emerged not only as a global leader in health resilience and innovation but also reaffirmed its role as the pharmacy of the world." He noted how India quickly expanded its healthcare infrastructure and increased vaccine production to meet both domestic and international demands.
Nadda also pointed out that the successful rollout of the Covid-19 vaccination program, which covered over a billion people, demonstrates the strength of India's healthcare system, the dedication of health workers, and sound policies. "As the pharmacy of the world, India played a important role in ensuring affordable access to essential medicines, vaccines, and medical supplies for nations across the globe," he added.
He then highlighted India's support for more than 150 countries during the pandemic, guided by the principle of "Vasudeva Kutumbakam," which means "the world is one family."
Nadda stressed that India is not just a participant in this dialogue but a partner in building a healthier and more resilient world. "The theme of this conference resonates deeply with our core belief that collaboration across borders, sectors, and disciplines is essential for creating lasting health solutions," he said.
"Eight drug testing labs are operational today, and two are in the pipeline. Eight mini testing labs are operational at different ports to conduct quick testing of imported materials. More than 95 percent of the regulatory process has been digitalized. The medical devices industry is also being regulated now. India remains fully committed to advancing global health. We believe in three 'S'--'Skill, Speed, and Scale.' By focusing on these three aspects, we have been able to meet the demand for pharma products while adhering to global quality standards," Nadda added.
He expressed hope that the conference would serve as a platform for exchanging knowledge and best practices, addressing issues related to drug and medical device regulation. The Minister said, "I am sure that the deliberations during the conference will culminate in concrete recommendations for actions by regulatory authorities and related institutions, paving the way to improve regulatory capacities in the coming two years before the next conference. I wish the conference a grand success."